Alvogen and its subsidiary Lotus Pharmaceuticals have settled patent litigation with Celgene concerning the originator’s Revlimid (lenalidomide). This allows for generic entry of the multiple myeloma treatment on a confidential date.
“As part of the settlement, the parties will file consent judgments with the US district court for the district of...




